Extrait

The primary objective is to assess the magnitude of potential risk of developing NSF with the administration of Primovist/Eovist in patients with moderate to severe renal impairment for the development of NSF, based on diagnostically specific clinical and histopathological information.

Critère d'inclusion

• Patients with moderate (eGFR 30 – 59 mL/min/1.73 m2) to severe renal impairment (eGFR < 30 mL/min/1.73 m2) scheduled to undergo contrast-enhanced MRI with Primovist/Eovist

Liens

• euctr
• euctr
• ictrp
• ictrp
• ictrp
• euctr